Melphalan+Autologous PBSCT+Lenalidomide Maintenance, Melphalan+Autologous PBSCT+Placebo Maintenance, Immunomodulators (IMiD), Newly Diagnosed Multiple Myeloma (NDMM), Phase 3
### Instruction:
Identify the study with the following condition. 
### Input:
Melphalan+Autologous PBSCT+Lenalidomide Maintenance, Melphalan+Autologous PBSCT+Placebo Maintenance, Immunomodulators (IMiD), Newly Diagnosed Multiple Myeloma (NDMM), Phase 3 
### Output:
Popular Name is CALGB, Study ID is NCT00114101